Synergistic effect of febantel and pyrantel embonate in elimination of Giardia in a gerbil model.
The objectives of the study were to determine the optimal dose of febantel, pyrantel embonate and a combination of febantel/pyrantel embonate required to effectively treat Giardia in a gerbil model and to determine if there is a synergistic effect with the two drugs. SPF gerbils were infected by oral inoculation with 105 Giardia duodenalis trophozoites (day 0). On days 5 to 7, animals (n = 6) were treated once daily via oral gavage with febantel, pyrantel embonate, febantel and pyrantel embonate, metronidazole or placebo. Gerbils were euthanised 24 hours after last treatment and duodenal trophozoites were enumerated on a haemocytometer to obtain a concentration of trophozoites/ cm of gut. Febantel alone, effectively eliminated Giardia trophozoites at 160 and 80 mg/kg. Pyrantel embonate did not eliminate Giardia from the animals but significantly reduced parasite counts at all dosages. Febantel combined with pyrantel embonate effectively eliminated Giardia trophozoites at 160, 80 and 40 mg/kg. Metronidazole did not eliminate Giardia trophozoites from the gut. All placebo-treated animals were heavily infected with Giardia trophozoites. It can be concluded that febantel is more effective in elimination of Giardia infections when combined with pyrantel embonate compared to the agents used alone.
Olson
Merle E
ME
Bow Valley Research, Calgary, Alberta Canada and Department of Biomedical Engineering, University of Alberta, Edmonton, Alberta. merle.olson@innovotech.ca
Heine
Josef
J
D000284:Administration, Oral; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004386:Duodenum / Q000469:parasitology; D005849:Gerbillinae; D005872:Giardia / Q000187:drug effects*; D005873:Giardiasis / Q000188:drug therapy*; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D011716:Pyrantel Pamoate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D006146:Guanidines; D008795:Metronidazole; D011716:Pyrantel Pamoate; C017309:febantel